The Landau Lab develops computational and experimental tools to study cancer evolution. Our research is geared towards uncovering basic principles in evolutionary biology, using both patient derived samples and experimental systems for modeling cancer evolution. In addition, we seek to apply this knowledge to designing the next generation of precision medicine tools to overcome cancer evolution, as a central challenge to cancer cure today.
+Dan Landau, MD, PhD
Dan A. Landau, MD, PhD, is a Core Member and Assistant Investigator at the New York Genome Center. He holds a joint appointment as Assistant Professor of Medicine in the Division of Hematology and Medical Oncology & the Department of Physiology and Biophysics at Weill Cornell Medicine.
Dr. Landau’s lab is working to discover fundamental principals in evolutionary biology and biological regulation of human cancer cells. The ultimate goal is to understand the basic dimensions that determine cancer’s evolution, in order to devise therapies that directly anticipate and address it.
Dr. Landau grew up in Tel Aviv, Israel where he obtained his MD from Tel Aviv University. He then went on to receive his PhD from Paris Diderot University in Paris, France. His most recent position was an Instructor of Medicine at Harvard Medical School, working at the Dana Farber Cancer Institute and the Broad Institute.
Dr. Landau has pioneered the study of intra-tumoral genetic and epigenetic diversity in patient samples, to enable the study of cancer evolution in its natural environment. His work was recognized with many honors including the Burroughs Wellcome Fund Career Award for Medical Scientists as well as the K01 award from the NIH Big Data to Knowledge initiative.
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A & Wu, CJ.
Nature Communications. 2017 Dec. 19.
Cancer Evolution: No Room for Negative Selection. Bakhoum SF, Landau DA.
Cell. 2017 Nov. 16.
Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N.
Nature Communications. 2017 Oct. 26.
Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution.
Bakhoum SF, Landau DA.
Cold Spring Harbor Perspectives in Medicine. 2017 June 1.
Genomic complexity of multiple myeloma and its clinical implications.
Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM.
Nature Reviews Clinical Oncology. 2017 February 14.
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.